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Background: Effective treatment options for nonresectable hepatic carcinoma
(HC) in dogs are limited.
Hypothesis/Objective: Objectives were to report outcomes, complications, and
tumor responses via computed tomography (CT) assessment after drug-eluting bead
transarterial chemoembolization (DEB-TACE) for nonresectable HC in dogs. The
authors hypothesized that major complications would be uncommon and short-term
CT assessment would demonstrate stable disease or partial response.
Animals: Client-owned dogs (n = 16) with nonresectable HC.
Methods: Prospective, single-arm clinical trial. Drug-eluting bead transarterial
chemoembolization was performed to varying levels of blood flow stasis. Computed
tomography imaging was compared before and approximately 12 weeks after initial
treatment.
Results: Drug-eluting bead transarterial chemoembolization was successfully admin-
istered in all attempts. Based on percent change in elliptical tumor volume response
(mL), stable disease (8/13; 62%) was the most common outcome followed by partial
response (3/13; 23%) and progressive disease (2/13; 15%) with a median of 74 days
(range, 39-125) after initial treatment. Median tumor volume (mL) after DEB-TACE
decreased in volume by 13% (range, 56% decrease to 77% increase). Mild complica-
tions consistent with postembolization syndrome occurred after 7/27 (26%) treat-
ments. Major complications occurred after 3/27 (11%) treatments: hepatic abscess/
Abbreviations: CT, computed tomography; CTA, computed tomography angiography; DEB-TACE, drug-eluting bead transarterial chemoembolization; HC, hepatic carcinoma; HCC, hepatocellular
carcinoma; MST, median survival time; PES, post-embolization syndrome; RECIST, Response Evaluation Criteria in Solid Tumors; TACE, transarterial chemoembolization; TAE, transarterial
embolization.
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septicemia (2) and cholecystitis/death (1), resulting in treatment-induced death after
2/27 (7%) treatments. Median survival time after treatment was 337 days (range,
22-1061). Dogs with a presenting complaint of weight loss (P = .02) had a significantly
shorter median survival time (126 days; range, 46-337) than those dogs without prior
history of weight loss (582 days; range, 22-1061).
Conclusions: Drug-eluting bead transarterial chemoembolization for nonresectable
HC is a feasible procedure, which promoted stable disease or partial response in 85%
of dogs in this study sample.
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1 | INTRODUCTION
Hepatic carcinomas (HCs) are the most common primary liver neo-
plasm in dogs with hepatocellular carcinoma (HCC) comprising the
most common subset,1-3 followed by bile duct carcinomas,2,4-6 and
hepatic neuroendocrine carcinomas.4,7,8 For massive, resectable HCs,
complete surgical resection is recommended.3,9,10 The prognosis for
dogs with focal, resectable HC is good with surgical intervention
(range, >1460 to >1836 days)3,9-11; however, there is minimal infor-
mation regarding the efficacy of nonsurgical treatment modalities for
nonresectable disease.
In humans, transarterial embolization (TAE) or transarterial
chemoembolization (TACE) are important components of treatment for
nonresectable HC.12-17 TAE involves transcatheter superselective arterial
injections of embolic agents into the tumor-feeding arteries resulting in
targeted ischemic necrosis.18,19 Drug-eluting bead TACE (DEB-TACE)
delivers higher doses of chemotherapeutic agents with longer drug-tumor
contact times by administering embolic beads which slowly elute chemo-
therapeutics locally, reducing systemic adverse effects.19 In people with
nonresectable HC, TACE shows improved median survival time (MST) vs
conservative management.20-24 Compared to conventional TACE, DEB-
TACE might show comparable or improved efficacy and fewer adverse
effects,25-30 leading to the current investigation of DEB-TACE in dogs.
The objectives of this study were to report outcomes, complica-
tions, and computed tomography (CT) elliptical tumor volume response
rates associated with administration of 100 to 300 μm doxorubicin
DEB-TACE to dogs with nonresectable HC. The authors hypothesized
that major31 complications associated with DEB-TACE treatment
would be uncommon and that diagnostic imaging would demonstrate
short-term stable disease (SD) or partial response after DEB-TACE.
2 | MATERIALS AND METHODS
2.1 | Case selection
Dogs diagnosed with nonresectable HC, either naïve tumors or those
with nonresectable regrowth after previous excision at The Animal
Medical Center, New York from April 2010 to July 2015 were pro-
spectively enrolled in the clinical trial and treated with DEB-TACE
after informed owner consent. The study was approved by the Institu-
tional Animal Care and Use Committee.
Dogs were included if a cytologic or histologic diagnosis of HC
was obtained and if the mass was determined by a surgeon to be non-
resectable without substantial risk when assessed by either preopera-
tive computed tomography angiography (CTA) or during exploratory
laparotomy. Dogs were excluded if they were treated with chemo-
therapy, radiation therapy, or surgical intervention other than surgical
biopsy within the previous 3 months.
Dogs were staged with standard techniques including physical
examination, 3-view thoracic radiography or thoracic CT scan, abdom-
inal CTA, complete blood cell count, serum biochemistry profile, rest-
ing bile acids, and urinalysis. The first treatment was performed within
30 days of staging.
2.2 | Medical records review
Medical records review was performed, and data recorded included
signalment (age, breed, and sex), weight, presenting clinical signs at
diagnosis of HC, prior surgeries, biopsy and cytologic findings, history
of abdominal effusion, diagnostic imaging findings and tumor volume
measurements, DEB-TACE procedural information and schedule,
duration of procedure, procedural complications, postprocedural com-
plications, survival times (STs), and necropsy results.
2.3 | Treatment protocol
Dogs were to receive 2 DEB-TACE procedures 6 weeks apart. The
goal of the initial DEB-TACE procedure was prolonged chemothera-
peutic drug-delivery through administration of drug-eluting beads
within the tumor while preserving blood flow through the lobar and
first-order hepatic arteries, enabling subsequent treatments. The goal
of the second treatment was to repeat chemotherapeutic drug-
delivery and then additionally provide embolization to vascular stasis,
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defined as no evidence of continued hepatic arterial flow to the tumor
or lack of tumor blush.32At the conclusion of the second treatment, if
vascular stasis had not yet occurred, additional nondrug loaded beads
(LC/DC Bead 100-300 μm hydrogel microspheres, Biocompatibles UK
Limited, Farnham, UK) were administered until vascular stasis was
achieved.
The DEB-TACE procedure was performed as described previ-
ously33-35 under general anesthesia via a femoral artery or carotid
artery approach (Micropuncture set, Infiniti Medical, Menlo Park, Cali-
fornia). After superselective hepatic arterial branch access to the main
arterial supply of the mass, 100 to 300 μm DEBs (LC/DC Bead
100-300 μm hydrogel microspheres, Biocompatibles UK Limited)
loaded with 30 mg/m2 of doxorubicin (or 1 mg/kg if under 10 kg)
(Adriamycin, doxorubicin hydrochloride, Pfizer Inc, Andover, Massa-
chusetts) was administered. Angiography was performed after each
DEB-TACE procedure to determine whether vascular stasis had been
achieved.
Dogs were discharged the day after the procedure and prescribed
omeprazole (Prilosec, Proctor and Gamble, Cincinnati, Ohio) (1 mg/kg PO
q12h for 7-14 days), ampicillin/clavulanate (Clavamox, Pfizer Animal
Health, Madison, New Jersey) (13.75 mg/kg PO q12h for 14 days),
ondansetron (Zofran, GlaxoSmithKline, Philadelphia, Pennsylvania)
(0.1-1 mg/kg PO q24h for 7 days), and prednisone (Prednisone, Roxane
Laboratories Inc, Columbus, Ohio) (1 mg/kg/d PO × 3 days, then
0.5 mg/kg/d PO × 3 days, then 0.5 mg/kg/d q48h for 3 doses.35
2.4 | Tumor response evaluation
All dogs had baseline multiphase (arterial with multiple venous phase)
abdominal CT angiography (CTA) performed within 2 days before ini-
tial DEB-TACE. Six weeks later, a second DEB-TACE treatment was
performed. After each treatment, a noncontrast abdominal CT was
performed under the same anesthetic even. A final multiphase CTA
was performed ~12 weeks after the first treatment in conjunction
with doxorubicin (Adriamycin, doxorubicin hydrochloride, Pfizer Inc,
Andover, Massachusetts) administered IV (as part of a separate phar-
macokinetics study) (30 mg/m2 IV once, or 1 mg/kg if a dog weighed
less than 10 kg). Three dogs (dogs 2, 7, and 11) did not have a follow-
up CTA performed after DEB-TACE; tumor response could not be
assessed for these dogs.
CTA image series were reviewed by a board-certified radiologist
(T. S.) and procedures performed using a dedicated workstation
(Syngo.via, Siemens AG, Erlangen, Germany) and oncological imaging
software (Syngo.MM Oncology, Siemens AG, Erlangen, Germany).
CTA's pre- and post-treatment were compared for the same individ-
ual. Subjective assessment was performed for hepatic lesion descrip-
tion (number of lesions and lobes involved). Manual correction of
hepatic lesion borders was performed after automatic delineation
(Syngo.via, Siemens AG; Syngo.MM Oncology, Siemens AG).
Response to treatment was generated by the system in tumor volume
(in mL).36,37 Elliptical tumor response was categorized as complete
response: complete resolution of all disease; partial response: ≥30%
decrease size; SD: percent difference in size between −30% and 20%;
and progressive disease ≥ 20% increase in size.38-40
2.5 | Complications
At each visit, a detailed history was obtained from the owner. Compli-
cations attributable to the procedure were considered mild if able to
be managed by either outpatient or inpatient interventions that did
not require anesthesia, or major if requiring urgent intervention under
anesthesia for resolution or resulting in death.31
2.6 | Statistical analysis
Survival time was defined as the duration from the date of DEB-TACE
treatment to the time of death. Descriptive measures were presented
as median and range or quantitative variables and frequency (percent-
age) for qualitative variables. Independent groups were compared
using Fisher for qualitative variables, and t test, Mann-Whitney or
Brunner-Munzel test for quantitative variables based on the assump-
tion of normality and equality of variances. Homoscedasticity was
tested using Levene test, and normality was tested using Shapiro-
Francia test. Survival curves were presented using Kaplan-Meier esti-
mator, and simple proportional hazard Cox models were fitted to
estimate hazard ratios with 95% confidence intervals. Marginal homo-
geneity was tested using McNemar test. Agreement was classified
based on the Kappa statistic based on 0 to 0.2 no agreement, 0.21 to
0.40 slight agreement, 0.41 to 0.60 moderate agreement, 0.61 to 0.80
substantial agreement, 0.81 to 1 almost perfect agreement.41 All
hypotheses were 2-sided at 5% significance level. Calculations were
performed using R-package, version 3.6.1 (R Core Team [2019]. R: A
language and environment for statistical computing. R Foundation for
Statistical Computing, Version 3.6.1, Vienna, Austria. https://www.R-
project.org/).
3 | RESULTS
Sixteen dogs diagnosed with nonresectable HC, either naïve tumors
(12/16; 75%) or those with suspected regrowth after previous exci-
sion (4/16; 25%) and treated with DEB-TACE at The Animal Medical
Center satisfied study inclusion criteria. There were 8 male castrated
dogs, 7 female spayed dogs, and 1 intact male. The median age at the
time of first treatment was 11.1 years (range, 5.8-13.2 years). The
median weight was 14.7 kg (range, 6.3-30.8 kg). Breeds represented
included Shih Tzu (3), Labrador retriever (1), German wirehaired
pointer (1), Schnauzer (1), Beagle (1), Australian Shepherd (1), Peking-
ese (1), and mixed breed (7). Presenting complaints at the time of HC
diagnosis and pertinent history are shown in Table 1. The diagnosis of
a high risk or nonresectable hepatic mass was determined via explor-
atory laparotomy in 10/16 dogs (62%) at referral surgical institutions
and via CT in 6/16 dogs (38%). The diagnosis of HCC was determined
ROGATKO ET AL. 3
via laparoscopic biopsy, ultrasound-guided needle core biopsy or sur-
gical biopsy in 15 dogs (15/16 dogs; 94%) and via fine-needle aspirate
cytology in 1 dog (1/16; 6%).
All dogs had an abdominal CTA performed 0 to 1 days before
treatment. On initial CTA, 12/16 (75%) had masses solely or including
the right side of the liver while 2/16 (12.5%) were solely left and 2/16
(12.5%) were centrally located masses.
Initial DEB delivery was technically successful in all dogs, meaning
that vascular access was achieved, the major feeding artery selected,
and the DEBs (LC/DC Bead 100-300 μm hydrogel microspheres,
Biocompatibles UK Limited) delivered. Fourteen out of 16 dogs (88%)
initially received a full 30 mg/m2 doxorubicin dose (Adriamycin, doxo-
rubicin hydrochloride, Pfizer Inc). Two dogs (dog 10 and 11) received
89% and 75% of the dose, respectively, before stasis was achieved,
preventing additional bead delivery. Four out of 16 dogs (25%) were
embolized to stasis at initial treatment. The median total procedural
duration was 85 minutes (range; 55-134).
A second DEB-TACE treatment was attempted in 11/15 (73%)
dogs; 1 dog (dog 2) developed fatal complications after the first DEB-
TACE (see Section 3.2). Two dogs had been embolized to stasis before
to receiving the full treatment volume and identifying an accessible
vascular supply to the tumor was considered unlikely. It was not clear
from the records why a second procedure was not pursued in 2 dogs.
All 11 dogs successfully received a second DEB-TACE treatment to
vascular stasis on the first attempt. Due to previous embolization to
stasis, 1 dog received 15% of the full treatment volume and stasis was
complete; the 10 remaining dogs embolized to stasis received a full
treatment volume. Four dogs had an additional 0.25 mL of DEBs
(without chemotherapy added) (LC/DC Bead 100-300 μm hydrogel
microspheres, Biocompatibles UK Limited) administered after adminis-
tration of the initial dose to achieve tumor stasis (dogs 3, 8, 9, 14).
The median total procedural duration was 91 minutes (range, 70-125).
3.1 | Chemotherapy administered IV
Nine out of 13 (69%) remaining dogs received a single intravenous
doxorubicin (Adriamycin, doxorubicin hydrochloride, Pfizer Inc)
TABLE 1 Associations of historical
signs and presenting complaint with
survival via univariable cox regression for
dogs with HC after DEB-TACE
Variable Count (%) Estimate (95% confidence interval) P value
History of previous hepatic mass resection 0.509 (0.157-1.65) .26
No 12 (75)
Yes 4 (25)
History of hemoabdomen 0.480 (0.110-2.14) .33
No 13 (81.3)
Yes 3 (18.8)
Presenting complaint of inappetence 1.51 (0.522-4.36) .45
No 10 (62.5)
Yes 6 (37.5)
Presenting complaint of weight loss 4.82 (1.23-18.9) .02*
No 11 (68.8)
Yes 5 (31.3)
Presenting complaint of lethargy 3.16 (0.695-14.4) .14
No 13 (81.3)
Yes 3 (18.8)
Presenting complaint of vomiting 2.59 (0.724-9.29) .14
No 11 (68.8)
Yes 5 (31.3)
Presenting complaint of diarrhea 2.64 (0.626-11.1) .19
No 13 (81.3)
Yes 3 (18.8)
Presenting for incidental blood work finding 0.906 (0.280-2.94) .87
No 12 (75)
Yes 4 (25)
Presence of concurrent neoplasia 0.732 (0.257-2.09) .56
No 8 (50)
Yes 8 (50)
Abbreviations: DEB-TACE, drug-eluting bead transarterial chemoembolization; HC, hepatic carcinoma.
*Bold values are statistical significance P < .05.
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treatment (30 mg/m2) at the time of second CTA. Three dogs did not
survive to repeat CTA. One dog developed complications from a
hepatic abscess and did not undergo repeat CT/chemotherapy. It was
unclear from the record why 2 dogs did not receive chemotherapy.
One dog developed systemic mastocytosis 1 month after DEB-TACE
treatments and received intravenous treatments of vinblastine and
toceranib phosphate over the next 2 months (dose regimen unknown)
after second CTA. Eleven (11/16; 69%) dogs received both DEB-
TACE treatments and 8/16 (50%) dogs received all 3 treatments (Two
DEB-TACE plus IV doxorubicin [Adriamycin, doxorubicin hydrochlo-
ride, Pfizer Inc] chemotherapy).
See Table 2 for tumor volume measurements before and after
embolization.
All 16 dogs were discharged from the hospital 1 to 2 days after
each DEB-TACE treatment.
3.2 | Complications
Eight out of 27 (30%) DEB-TACE treatments resulted in mild complica-
tions31 in 6 individual dogs. Seven out of 27 (26%) treatments resulted in
5 dogs displaying signs of gastrointestinal disease <14 days after
DEB-TACE consistent with postembolization syndrome (PES), considered
to be a mild complication.31 Signs of PES included vomiting (3/27; 11%),
diarrhea (5/27; 19%), lethargy (1/27; 4%), and hyporexia (5/27; 19%).
Postembolization syndrome signs occurred after both treatments in
2 dogs, after the first treatment in 1 dog and after the second treatment
in 2 dogs. There was no association between the development of PES
after the first treatment and the development of PES after the second
treatment (P = 1.00). Embolization to stasis during either treatment was
not associated with the development of PES (P = 1.00). A history of
vomiting, diarrhea, or inappetence was not associated with the develop-
ment of PES after DEB-TACE (P = .47, .48, .4). There was no association
between tumor size (mL or mL/kg) on pretreatment CT and the develop-
ment of PES after the first treatment (P = 1.00, .53). There was no associ-
ation between change in tumor size and the development of PES (P = .8).
Two dogs developed hemoabdomen 24 hours after initial DEB-
TACE; both required blood transfusions but not surgical intervention.
None of the dogs with hemoabdomen reported before the DEB-TACE
developed hemoabdomen after DEB-TACE. The development of a
hemoabdomen after the first embolization was not associated with
the development of PES after the first treatment (P = 1.00). Both dogs
went on to receive a second DEB-TACE treatment without develop-
ment of hemoabdomen. The development of a hemoabdomen after
initial DEB-TACE was not associated with mass size on pre-CT (vol-
ume, P = .49; volume/body weight P = .53).
Three out of 27 (11%) DEB-TACE treatments resulted in major
complications.31One dog became anorexic 16 days after DEB-TACE
and discharge from hospital. Bile peritonitis was diagnosed. The dog
was euthanized due to gall bladder rupture suspected to be secondary
to an acute infarct 3 weeks after DEB-TACE. After the second treat-
ment, 2 dogs of 11 dogs (18%) developed major complications.31 One
dog presented 4 days after discharge with abdominal pain, vomiting,
and fever. Abdominal exploratory revealed a septic abdomen with a
nonresectable hepatic abscess and hepatic mass with severe hemor-
rhage. Euthanasia was elected. One dog developed a hepatic abscess
several weeks after the second DEB-TACE procedure. The
methicillin-resistant Staphylococcus pseudintermedius abscess eventu-
ally ruptured and the septic peritonitis was managed with oral and
injectable antibiotics, surgical drainage, and multiple percutaneous
drainages with resolution 8 months later. Ultimately, 2/16 dogs (13%)
or 2/27 treatments (7%) resulted in death. Embolization to stasis in
the first or second treatment was not associated with major complica-
tions (P = .23, P = 1.00). Two dogs that developed hepatic
abscessation had tumor volumes (239 mL, 172 mL) and tumor vol-
ume/body weight (13.5 mL/kg, 8.43 mL/kg) smaller than the median
values (285 mL, 30.0 mL/kg) for the study group. There was no asso-
ciation between a history of weight loss and complications after
embolization (P = .3).
3.3 | Long-term outcomes
Median survival time for all of the dogs from the first DEB-TACE
treatment to date of death was 337 days (range, 22-1061) (Kaplan-
Meier survival curve, Figure 1). A presenting complaint of weight loss
TABLE 2 Computed tomography tumor volume measurements before and after DEB-TACE for dogs with HC as risk factors for survival
CT tumor size measurement
Median (range) P value Median (range) P value Median (range) P value
Before DEB-TACE After DEB-TACE Percent change following DEB-TACE
Volume (mL) 281 (48.7-1580) .13 258 (45.0-1301) .15 −13% (−56% to 77%) .39
Volume/body weight (mL/kg) 30.0 (5.70-87.3) .03* 25.7 (3.90-117) .02*
Ellipsoid tumor response classification Complete response 0 (0%) N/A
Partial response 3 (23%)
Stable disease 8 (62%)
Progressive disease 2 (15%)
Change in size Decreased 10 (77%) .12
Increased 3 (23%)
Abbreviations: DEB-TACE, drug-eluting bead transarterial chemoembolization; HC, hepatic carcinoma.
*P < .05.
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was the only clinical/historical sign predictive of death (P = .02). Dogs
with a history of weight loss had a significantly reduced ST of
126 days (range, 46-337) compared to those dogs without a prior his-
tory of weight loss (582 days; range, 22-1061) (Figure 2).
If the 2 dogs that died from treatment related complications were
excluded from analysis, the MST for dogs without fatal procedural
complications was 448 days (range, 61-1061). Ten of 16 (63%) dogs
were suspected to have died as a result of HC or DEB-TACE. Having
mild or severe complications after the first or second embolization
was not associated with survival (P = .07, .99).
There was no association between PES, or specifically diarrhea,
after the first embolization (P = .55, P = .99) or second embolization
(P = .62, P = .95) and survival. Development of a hemoabdomen after
DEB-TACE was not associated with survival (P = .99). For the 2 dogs
with a hemoabdomen after the procedure, 1 dog survived 582 days
after-DEB-TACE and was ultimately euthanized due to an unknown
reason, and the other dog was euthanized 337 days after DEB-TACE
because of a suspected hemoabdomen.
There was no association between the date of the first treatment
and death as a result of the treatment, implying the absence of a sub-
stantial learning curve (P = .28).
There was no association between whether the first embolization
was taken to stasis (P = .88) or whether there were complications
after the first embolization (P = .62) and survival. There was no associ-
ation between whether the second embolization was taken to stasis
(P = .99) or whether there were complications after the second embo-
lization (P = .6) and survival.
There was no association between tumor volume (mL) on pre-
treatment CT and survival (P = .13). There was a statistically significant
association between larger tumor volume/body weight (mL/kg) on
pretreatment CT and shorter survival (P = .03). There was no associa-
tion between post-treatment CT tumor volume (mL) and survival
(P = .15); however, there was again a statistically significant associa-
tion between post-treatment CT larger tumor volume/body weight
(mL/kg) and shorter survival (P = .02). CT tumor response criteria
which were not significantly associated with survival included percent
change in tumor volume, or percent change in tumor volume adjusted
for bodyweight before or after treatment (P = .39, P = .39). There was
no association between a history of weight loss and tumor size as vol-
ume (mL) or volume/body weight (mL/kg) (P = .44, P = .18).
3.4 | Necropsy
Six out of 16 dogs (38%) had full (4/6; 67%) or partial (2/6; 33%) nec-
ropsy reports available; 2 out of 6 necropsy reports were limited in
scope with the necropsy report of 1 dog was limited to the hepatic
mass and the necropsy report of another dog was limited to the liver
and gallbladder. Five out of 6 necropsy reports (83%) confirmed
regrowth of HCC; the final necropsy report was consistent with
HC. One dog had incompletely resected HCC with vascular invasion
diagnosed via excisional biopsy 1608 days before DEB-TACE with
suspected HCC regrowth on CT; however, necropsy results were con-
sistent with focal and metastatic HC, suspected to be of
F IGURE 1 Kaplan-Meier survival curve (solid line) and associated
95% confidence intervals for 16 dogs with HC treated with DEB-
TACE. DEB-TACE, drug-eluting bead transarterial chemoembolization;
HC, hepatic carcinoma
F IGURE 2 Kaplan-Meier survival curves and associated 95%
confidence intervals for 16 dogs with HC treated with DEB-TACE
with (blue) and without (red) a clinical history of weight loss. DEB-
TACE, drug-eluting bead transarterial chemoembolization; HC,
hepatic carcinoma
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neuroendocrine origin. With suspected metastatic neuroendocrine
carcinoma to the liver and lungs on necropsy, dog 13's necropsy
report was the only necropsy report to describe distant metastasis.
Two out of 5 (40%) necropsy reports describing the gallbladder
reported cholecystitis. Both of these dogs had tumors adjacent to the
gallbladder. Cholecystitis was mild in 1 dog and severe in another. His-
topathology revealed thrombosis and DEBs (LC/DC Bead
100-300 μm hydrogel microspheres, Biocompatibles UK Limited)
within gallbladder vessels adjacent to the rupture suggestive of an
acute infarct in 1 dog which who was euthanized due to gall bladder
rupture. Five out of 6 (83%) necropsy reports described intratumoral
DEBs present between a median of 530 days (range, 22-1007 days)
after the second treatment (LC/DC Bead 100-300 μm hydrogel micro-
spheres, Biocompatibles UK Limited). There was no association
between the presence of cholangiocystitis (P = .62) or the presence of
intralesional beads (LC/DC Bead 100-300 μm hydrogel microspheres,
Biocompatibles UK Limited) on necropsy and survival (P = .29).
4 | DISCUSSION
There are currently no established therapeutic recommendations for
dogs with metastatic, nonresectable, or incompletely excised HC.42
The results of this study showed that DEB-TACE treatment for
nonresectable HC could be performed successfully, resulted in few
major complications, and resulted in 77% of tumors displaying a
reduction in volume on follow-up CTA. Drug-eluting bead transarterial
chemoembolization could emerge as a viable treatment alternative for
dogs with nonresectable HC.
In DEB-TACE in people, the most common complications after
embolization are minor and include PES, a syndrome mediated by an
inflammatory response to the embolization/chemotherapeutic agent,
manifesting in self-limiting abdominal pain, nausea, fever, and fatigue
within 14 days of treatment.19,43,44 In people, PES is associated with a
2-fold increased risk of death.43 The current study failed to demonstrate
an association between PES in dogs and reduced STs; however, the study
population was small and the lack of significance could be attributed to a
type II statistical error. In people, diarrhea is a less common complication
after DEB-TACE, occurring about in ~1.6% of humans.45 Conversely,
5/27 (19%) of DEB-TACE treatments resulted in transient diarrhea in the
dogs in this study; prophylactic treatment should be considered.
The complications of hepatic abscess and cholecystitis occurred
after 3/27 (11%) of treatments in dogs in this study. Embolization of
the cystic artery, chemotherapeutic injury to bile ducts, deposition of
lipiodol into the gallbladder wall, bacterial translocation from a
necrotic embolized tumor, and the local immunosuppression from
chemotherapeutics might contribute to these complications.44,46,47 In
human medicine, the addition of local high-dose antibiotics with
embolics might reduce hepatic abscessation and could be investigated
in dogs.46 Larger tumors and increased quantities of embolics are
linked to hepatic abscessation in people.44 The relatively larger tumors
treated in dogs might contribute to the higher risk of subsequent
abscessation.
Hemoabdomen after TACE is a rare complication with in people
with a risk of 0.2% to 0.4% per procedure and more common in larger,
heterogeneous, subcapsular, exophytic tumors; these are common
characteristics of nonresectable HC in dogs.48-50 In this study,
hemoabdomen developed after 2 treatments (2/27; 7%). They were
treated with packed red blood cell transfusions and survived to dis-
charge for 337 days and 582 days, respectively. Postoperative
hemoabdomen did not affect long-term survival; however, this study
had a small sample size, and a type II statistical error is possible. Sub-
jectively, HCC in dogs tends to be larger and more cavitated com-
pared to HCC in people, potentially increasing the risk of tumor
rupture.
While this study showed no survival benefit of embolization to
blood flow stasis, complications were comparable between both
groups suggesting that more aggressive embolizations might be safe
to perform. The small population also increases the risk of a type II
statistical error. There were some dogs in which repeat embolizations
were anticipated to be more difficult if the prior treatment had been
performed to stasis, suggesting that if repeat procedures are planned,
embolization to blood flow stasis during the initial treatment might be
avoided, or more time should be allowed to pass between subsequent
treatments. However, this study demonstrates the technical feasibility
of pursuing a second DEB-TACE treatment in 2 dogs that were previ-
ously embolized to blood flow stasis.
Clinical presentation might help identify dogs most likely to bene-
fit from DEB-TACE. Dogs presenting with weight loss before TACE-
DEB were identified to have a shorter MST in this study; 126 days
MST if prior history of weight loss vs 582 day MST without prior his-
tory of weight loss. This could be due to a more biologically malignant
behavior of tumors resulting in systemic weight loss, or comorbidities
which were not completely captured by any of the other parameters
evaluated.
Limitations of this study included variability in treatment proto-
cols, absence of reference or negative control groups, small sample
size, lack of additional follow-up imaging, and the absence of modified
response evaluation criteria in solid tumors and tumor perfusion to
assess CT data. The small sample size allows for the high risk of a
type II statistical error, so nonsignificant results should be interpreted
with caution. Future studies comparing DEB-TACE alone and in com-
bination with other treatment modalities should be considered.
4.1 | Clinical relevance
This study demonstrated the feasibility and safety of performing
DEB-TACE for nonresectable HC which promoted partial response in
23% of dogs, short-term SD or partial response in 85% of dogs, and
77% of the tumor volumes reducing in size after treatment. These
early results justify additional controlled clinical trials comparing DEB-
TACE to other treatment modalities. A significant relationship
between pre-DEB-TACE and post-DEB-TACE CT tumor volume
divided by body weight was found to significantly predict survival.
Dogs with a smaller tumor burden (relative to body weight) survived
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longer. Additionally, dogs with a presenting complaint of weight loss
had a significantly shorter MST than those dogs without prior history
of weight loss.
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